Cryptococcus neoformans is an opportunistic fungal pathogen that is inhaled into the lungs and can lead to life-threatening meningoencephalitis in immunocompromised patients. Currently, the molecular mechanisms that regulate the mammalian immune response to respiratory cryptococcal challenge remain poorly defined. DAP12, a signaling adapter for multiple pattern recognition receptors in myeloid and natural killer (NK) cells, has been shown to play both activating and inhibitory roles during lung infections by different bacteria and fungi. In this study, we demonstrate that DAP12 plays an important inhibitory role in the immune response to C. neoformans. Infectious outcomes in DAP12 ؊/؊ mice, including survival and lung fungal burden, are significantly improved compared to those in C57BL/6 wild-type (WT) mice. We find that eosinophils and macrophages are decreased while NK cells are increased in the lungs of infected DAP12 ؊/؊ mice. In contrast to WT NK cells, DAP12 ؊/؊ NK cells are able to repress C. neoformans growth in vitro. Additionally, DAP12؊/؊ macrophages are more highly activated than WT macrophages, with increased production of tumor necrosis factor (TNF) and CCL5/RANTES and more efficient uptake and killing of C. neoformans. These findings suggest that DAP12 acts as a brake on the pulmonary immune response to C. neoformans by promoting pulmonary eosinophilia and by inhibiting the activation and antifungal activities of effector cells, including NK cells and macrophages.T he environmental encapsulated yeast Cryptococcus neoformans is a common cause of invasive fungal infections in immunocompromised patients, including those with AIDS, solid organ transplants, and hematologic malignancies (1). When C. neoformans cells are inhaled into the lung, healthy individuals typically clear the infectious particles in an asymptomatic manner. However, in immunocompromised hosts, C. neoformans can proliferate in the lung, disseminate to the brain, and cause meningoencephalitis. Despite contemporary combination antifungal therapy, the survival rate for disseminated cryptococcosis approaches only 70% (2). Furthermore, the at-risk population for cryptococcosis is expanding due to the development and increased availability of novel immunosuppressive regimens for autoimmunity, transplantation, and cancer.An important approach to developing more efficacious therapies for cryptococcosis is to decipher the initial immune response in the lung that regulates fungal proliferation and tissue invasion. Classically, host defenses are triggered when fungal pathogen-associated molecular patterns (PAMPs) are detected by immune cell pattern recognition receptors (PRRs), such as C-type lectin receptors (CLRs) or Toll-like receptors (TLRs). Studies on the intracellular signaling molecules CARD9 (3) and MyD88 (4-6), which can mediate events downstream of CLRs and TLRs or interleukin-1 receptor superfamily members, respectively, suggest that these pathways play a role in mounting an effective immune response to C. neoformans. However, so f...